StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.57−0.08 (-1.50%)

Close on Nov 17, 2026Market cap $482.87MP/E –Yield –

Earnings

Valneva's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2025
€49.20M
EPS, Q1 FY2025
–
Latest guidance
Issued
Mar 18, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Valneva's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 18, 2026during market hours–––Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours€49.20M––Release
Q4 FY2024ended Dec 31, 2024Mar 20, 2025before the open–––Release
Q4 FY2023ended Dec 31, 2023Feb 15, 2024before the open–––Release
Q4 FY2022ended Dec 31, 2022Feb 16, 2023before the open–––Release
Q1 FY2022ended Mar 31, 2022May 5, 2022after the close–––Release
Q4 FY2021ended Dec 31, 2021Feb 4, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Valneva's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenuesFY2025180 – 190180 – 190ReaffirmedMay 7, 2025
Product salesFY2025170 – 180170 – 180RaisedMay 7, 2025
Total R&D investmentsFY202590 – 10090 – 100LoweredMay 7, 2025
Total revenuesFY2026155 – 170–NewMar 18, 2026
product salesFY2026145 – 160–NewMar 18, 2026

Guidance history

Every forecast Valneva put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 18, 2026product salesFY2026145 – 160New
Mar 18, 2026Total revenuesFY2026155 – 170New
May 7, 2025Product salesFY2025170 – 180Raised
May 7, 2025Total R&D investmentsFY202590 – 100Lowered
May 7, 2025Total revenuesFY2025180 – 190Reaffirmed
Mar 20, 2025Product salesFY2025170 – 180New
Mar 20, 2025Total R&D investmentsFY202590 – 100Lowered
Mar 20, 2025Total revenuesFY2025180 – 190New
Feb 15, 2024Other incomeFY202495 – 105New
Feb 15, 2024R&D expensesFY202465 – 90Lowered
Feb 15, 2024Product salesFY2024150 – 180New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Valneva filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?